https://pharmakonadvisors.com/https://pharmakonadvisors.com/431-2/https://pharmakonadvisors.com/about-us/https://pharmakonadvisors.com/akebia-secures-100-million-non-dilutive-term-loan-financing-reports-third-quarter-2019-financial-results/https://pharmakonadvisors.com/amicus-therapeutics-acquires-gene-therapy-portfolio-of-ten-clinical-and-pre-clinical-stage-aav-programs-in-neurologic-lysosomal-storage-disorders/https://pharmakonadvisors.com/atec-spine-inc-reports-third-quarter-2024-financial-results-and-raises-full-year-guidance/https://pharmakonadvisors.com/biocryst-refinances-existing-debt-with-450-million-financing-commitment-from-pharmakon/https://pharmakonadvisors.com/biopharma-credit-plc-us-762-million-ipo-and-admission-to-trading-on-the-london-stock-exchange-bringing-total-capital-raised-by-pharmakon-funds-to-us-2-4-billion/https://pharmakonadvisors.com/coherus-biosciences-secures-credit-financing-with-pharmakon-advisors/https://pharmakonadvisors.com/collegium-announces-closing-of-the-nucynta-franchise-acquisition/https://pharmakonadvisors.com/collegium-to-acquire-biodelivery-sciences-broadening-pain-portfolio/https://pharmakonadvisors.com/collegium-to-acquire-ironshore-therapeutics-expanding-into-neurology/https://pharmakonadvisors.com/corcept-therapeutics-announces-30-million-synthetic-capped-royalty-transaction-terminates-committed-equity-financing-facility-2/https://pharmakonadvisors.com/depomed-announces-prepayment-of-100-million-of-secured-debt-facility/https://pharmakonadvisors.com/depomed-secures-575-million-debt-facility-from-deerfield-and-pharmakon-to-finance-the-closing-of-nucynta-acquisition-2/https://pharmakonadvisors.com/evolus-enters-into-125-million-credit-facility-with-pharmakon-advisors/https://pharmakonadvisors.com/evolus-strengthens-balance-sheet-with-refinancing-reducing-cost-of-capital-and-expanding-financial-flexibility/https://pharmakonadvisors.com/geron-corporation-announces-up-to-375-million-in-funding-with-royalty-pharma-and-pharmakon-advisors/https://pharmakonadvisors.com/home/https://pharmakonadvisors.com/immunocore-reports-third-quarter-2022-financial-results-and-provides-business-update-immunocore/https://pharmakonadvisors.com/immunogen-signs-loan-agreement-with-pharmakon-for-up-to-125m/https://pharmakonadvisors.com/insmed-announces-strategic-financings-totalling-775-million/https://pharmakonadvisors.com/insmed-renegotiates-term-loan-with-pharmakon-resulting-in-a-lower-cost-of-capital-and-an-additional-150-million-in-proceeds-to-be-received-in-the-fourth-quarter/https://pharmakonadvisors.com/novocure-announces-75-million-drawdown-under-its-term-loan-agreement-through-pharmakon-advisors/https://pharmakonadvisors.com/novocure-announces-100-million-term-loan-agreement-with-pharmakon-advisors-2/https://pharmakonadvisors.com/novocure-secures-new-150-million-non-dilutive-term-loan-financing/https://pharmakonadvisors.com/novocure-secures-new-400-million-multi-tranche-non-dilutive-debt-financing-from-pharmakon-novocure/https://pharmakonadvisors.com/optinose-announces-150-million-debt-financing-from-pharmakon/https://pharmakonadvisors.com/paratek-pharmaceuticals-completes-acquisition-of-optinose-creating-an-expanded-portfolio-of-specialty-therapies/https://pharmakonadvisors.com/paratek-pharmaceuticals-completes-combination-with-radius-health-expanding-its-multi-product-specialty-commercial-platform/https://pharmakonadvisors.com/pharmakon-advisors-provides-275-million-debt-facility-to-reata-pharmaceuticals/https://pharmakonadvisors.com/precigen-announces-up-to-125-million-non-dilutive-financing/https://pharmakonadvisors.com/search/https://pharmakonadvisors.com/tarsus-strengthens-financial-position-and-refinances-existing-debt-with-200-million-non-dilutive-financing-commitment-from-pharmakon/https://pharmakonadvisors.com/team-members/https://pharmakonadvisors.com/transactions/https://pharmakonadvisors.com/urogen-secures-100-million-non-dilutive-term-loan-financing-with-pharmakon-advisors-allowing-funding-to-cash-flow-breakeven/https://pharmakonadvisors.com/valneva-strengthens-financial-position-by-refinancing-debt-with-pharmakon-advisors-and-provides-business-updates/https://pharmakonadvisors.com/zenas-biopharma-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-corporate-update/